Abstract 196P
Background
Noninvasively collected samples are attracting significant interest as new areas of biomarker study in immune checkpoint inhibitors (ICIs) field, and metabolomics is one of these growing ones. We focused on the added value of the metabolomic profile as a means of distinguishing long-term survival from short-term survival in NSCLC patients treated with ICIs.
Methods
We prospectively recruited 97 patients with stage IV NSCLC who were treated with anti-PD-1 inhibitor, including patients treated with monoimmunotherapy as second-line treatment (Cohort 1), and patients treated with combination immunotherapy as first-line treatment (Cohort 2). Each cohort was divided into two groups, long-term survival and short-term survival. All blood samples were collected before beginning immunotherapy. Metabolomic profiling of serum was performed by UHPLC-Q-TOF MS analysis. Multivariate data analysis, including Pareto-scaled principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA), was performed.
Results
A total of 41 differential metabolites in Cohort 1 and 47 in Cohort 2 were screened. Among them, 8 common metabolites in ESI- mode and 11 in ESI+ mode were significantly associated with both PFS and OS in cohort 1. In cohort 2, 3 metabolites in ESI- mode and 6 in ESI+ mode were significantly associated with both PFS and OS. In cohort 1, the top 3 enriched KEGG pathways, as determined through significant differential metabolic pathway analysis, were primary bile acid biosynthesis, african trypanosomiasis, and choline metabolism in cancer. In Cohort 2, the top 3 enriched KEGG pathways were the citrate cycle (TCA cycle), PPAR signaling pathway, and primary bile acid biosynthesis. The primary bile acid synthesis pathway had significant differences in the long-term survival and short-term survival groups in both Cohort 1 and Cohort 2.
Conclusions
Our study suggests that peripheral blood metabolomic analysis is critical for identifying metabolic biomarkers and metabolic pathways responsible for the NSCLC patients treated with ICIs, and the primary bile acid synthesis pathway may be the important one.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
the Science and Technology Program for Health and Medicine in Zhejiang Province, China (Grant No. 2021KY541), and the Natural Scientific Foundation of Zhejiang Province, China (Grant No. LY19H160007).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Clinical and molecular features of PTCH1 mutant in solid tumors
Presenter: Xuezheng Li
Session: Poster session 01
218P - Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Presenter: WON SUK LEE
Session: Poster session 01
219P - Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Presenter: Eloisa Jantus Lewintre
Session: Poster session 01
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01
221P - Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
Presenter: Chan Kim
Session: Poster session 01
222P - Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
Presenter: Natalie Cook
Session: Poster session 01
223P - Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Presenter: Gianluca Mauri
Session: Poster session 01
224P - Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Presenter: Afaf Abed
Session: Poster session 01
225P - Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country
Presenter: Milton Lombana Quinonez
Session: Poster session 01
226P - LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Presenter: Jiangfeng Ye
Session: Poster session 01